MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
Outlook Therapeutics ROCE Ratio 2011-2026 | OTLK
Annual ROCE Ratio Outlook Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98.12 | 367.97 | -721.92 | -1122.68 | -944.73 | 793.26 | 303.78 | 448.29 | -1583.27 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 793.26 | -1583.27 | -262.35 |
Quarterly ROCE Ratio Outlook Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 157.84 | 123.48 | 146.86 | 127.9 | 103.83 | 79.9 | 409.57 | 715.86 | 636.55 | 164.92 | -396.89 | -811.34 | -798.72 | -726.1 | -995.36 | -1000.59 | -1009.15 | -846.74 | -964.86 | -761.45 | -564.84 | -673.85 | 421.7 | 343.29 | 234.27 | 246.73 | 167.82 | 161.09 | 174.79 | 148.54 | 179.07 | 172.61 | 141.9 | 210.74 | 912.98 | 1314.77 | 1649.5 | 1621.83 | 875.45 | 472.23 | 74.21 | 74.21 | 20.37 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1649.5 | -1009.15 | 63.6 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K |  USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
-194.87 | $ 0.91 | 2.24 % | $ 849 K | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.4 | 1.63 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
-24.77 | $ 2.51 | 27.16 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
-43.85 | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 94.64 | -0.9 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-22.12 | $ 85.79 | 3.72 % | $ 7.25 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
-201.42 | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
-114.81 | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-7.03 | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
-76.05 | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-31.68 | $ 41.6 | 19.64 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |